Nautilus Biotechnolgy
NAUT
73 hedge funds and large institutions have $186M invested in Nautilus Biotechnolgy in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 25 reducing their positions, and 8 closing their positions.
720% more call options, than puts
Call options by funds: $41K | Put options by funds: $5K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.56% less ownership
Funds ownership: 51.11% → 50.55% (-0.56%)
3% less capital invested
Capital invested by funds: $191M → $186M (-$5.04M)
4% less funds holding
Funds holding: 76 → 73 (-3)
32% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 25
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$451K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$224K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$118K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84K |
| 5 |
CGL
Clarius Group LLC
Seattle,
Washington
|
+$62.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.35M |
| 2 |
BlackRock
New York
|
-$459K |
| 3 |
CC
Clearline Capital
New York
|
-$186K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$168K |
| 5 |
Barclays
London,
United Kingdom
|
-$96K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$28.4K | -9,500 | Closed |
|
|
MLICM
77
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$2.4K | -803 | Closed |
|
78
Simplex Trading
Chicago,
Illinois
| – | -$1.76K | -620 | -74% |
|
79
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$33 | -11 | Closed |
|
80
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$9 | +3 | New |
|
NAUT Hedge Fund Activity: Q1 2024 in Review
73 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q1 2024, worth a combined $186M — down 2.6% from $191M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NAUT and 5 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 17 added.
The largest buyer was Wexford Capital, opening a new position worth an estimated $451K. The largest seller was Morgan Stanley, cutting an estimated $1.35M.
- 73 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q1 2024, down from 76 in Q4 2023.
- Funds reported $186M of Nautilus Biotechnolgy stock for Q1 2024, down 2.6% quarter-over-quarter.
- 5 funds opened new Nautilus Biotechnolgy positions in Q1 2024 and 8 closed out, a net change of -3 holders.
- The largest Nautilus Biotechnolgy buyer in Q1 2024 was Wexford Capital, an estimated $451K added.
- The largest Nautilus Biotechnolgy seller in Q1 2024 was Morgan Stanley, an estimated $1.35M sold.
Based on aggregated 13F filings for Q1 2024.